SRZNW
Surrozen Inc. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-5.70
Beta
0.52
52W High
$0.03
52W Low
$0.00
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Surrozen Inc. Warrant
Surrozen Inc. is an innovative biotechnology company focused on developing breakthrough therapeutics for complex diseases through its proprietary platform emphasizing targeted biology. By specializing in antibody therapeutics for tissue-specific delivery, Surrozen aims to effectively modulate critical biological pathways linked to various diseases. The company boasts a robust pipeline of candidates across multiple development stages, reflecting its commitment to transformative treatment solutions. With a highly experienced team and strategic collaborations, Surrozen is poised to significantly advance the field of regenerative medicine, potentially redefining standard care for patients.
Fundamentals
| Revenue (TTM) | $3.48M |
| Gross Profit (TTM) | $-25.89M |
| EBITDA | $-41.55M |
| Operating Margin | -2394.00% |
| Return on Equity | -62.80% |
| Return on Assets | -35.70% |
| Revenue/Share (TTM) | $0.47 |
| Book Value | $-19.21 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -19.40% |
| Shares Outstanding | 0 |
| Float | $5.42M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 4/9/2026